Abstract
Background Numerous studies have shown that elderly women with endometrial cancer (EC) have a higher risk of recurrence and cancer-related death. It is, however, unclear whether aging is a causal prognostic factor, or whether other risk factors become increasingly common with age. We address to this with a unique multi-method study design using state of the art statistical and causal inference techniques on datasets of three large randomised trials.
Methods Data of 1801 women participating in the randomised PORTEC-1, -2 and -3 trials were used for statistical analyses and causal inference. The cohort included 714 patients with intermediate-risk EC, 427 high-intermediate risk EC patients and 660 high-risk EC patients. Associations of age with clinicopathological and molecular features were analysed using non-parametric tests. Multivariable competing risk analyses were performed to determine the independent prognostic value of age. To analyse age as a causal prognostic variable a deep learning Causal Inference model called AutoCI was used.
Findings Median follow-up was 12·3 years for PORTEC-1, 10·5 years for PORTEC-2 and 6·1 years for PORTEC-3. Both overall recurrence and EC-specific deaths significantly increased with age. Moreover, elderly women had a higher incidence of deep myometrial invasion, serous tumour histology and p53abn tumours. Age was an independent risk factor for both overall recurrence (HR 1·02 per year, 95%CI 1·01-1·04; p=0·0012) and EC-specific death (HR 1·03 per year, 95%CI 1·01-1·05; p=0·0012), and was identified as a significant causal variable.
Interpretation This study shows that advanced age is associated with more aggressive tumour features, and independently and causally related to worse oncological outcomes. Therefore, treatment for endometrial cancer in elderly women should not be de-escalated based on their age alone.
Funding The PORTEC-1, -2 and -3 trials and the associated translational studies are supported by the Dutch Cancer Society.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
All PORTEC clinical trials were supported by a clinical trial grant from Dutch Cancer Society. There was no financial support for the current project and analysis.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical permission was obtained from all participating centres for the PORTEC-1, -2 and -3 trials.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets used in this study are not publicly available due to restrictions by privacy laws. Data from PORTEC-1 and PORTEC-2 trial are held by the PORTEC study group and data from the PORTEC-3 trial are available to members of the international TransPORTEC Research Consortium. Requests for sharing of all data and material should be addressed to the corresponding author within 15 years of the date of publication of this Article and include a scientific proposal. Depending on the specific research proposal, the TransPORTEC consortium (PORTEC-3 study) or the PORTEC study group (PORTEC-1, PORTEC-2), will determine when, for how long, for which specific purposes, and under which conditions the requested data can be made available, subject to ethical consent.
